Patients with diabetes mellitus (DM) have accelerated atherosclerosis progression and increased cardiovascular morbidity and mortality. Therefore, patients with type 2 DM (T2DM) are increasing in the general population, and they have a higher risk of cardiovascular diseases (CVDs) than patients without T2DM [1]. However, the mechanisms underlying the increased CVD risk of patients with T2DM and atherosclerosis progression are not completely understood. One possible mechanism is the increased production of advanced glycation and lipoperoxidation end products, such as malondialdehyde (MDA) and lysophosphatidylcholine, implicated in the oxidation of low-density lipoprotein (LDL) particles, one of the main atherogenic components associated with CVD risk [2,3].
